Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

See Locations Near You

Summary

The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following HLA matched allogeneic hematopoietic cell transplant

eligible for DLI
no evidence of GVHD
stable immunosuppressive regimen
adequate renal and liver function Exclusion Criteria:- CML patients who have not received DLI, active infections

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT00185757

Recruitment Status:

Unknown status

Sponsor:

Robert Negrin

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University School of Medicine
Stanford California, 94305, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT00185757

Recruitment Status:

Unknown status

Sponsor:


Robert Negrin

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider